Email Contact Phone Company Visit Website

Location Office

Kungsgatan 36
Stockholm
SE

NASDAQ OMX New York Head Office

One Liberty Plaza
New York
NY
US

NASDAQ OMX Stockholm Office

Tullvaktsvägen 15
Stockholm
SE

NASDAQ OMX Rockville Office

805 King Farm Boulevard 1st and 2nd floor
Rockville
MD
US

NASDAQ OMX London Office

Woolgate Exchange, 25 Basinghall Street, City of London
London
GB

NASDAQ OMX New York Office

Marketsite 4 Times Square
New York
NY
US

NASDAQ OMX Hong Kong Office

Room 1207-8, 12/F Man Yee Building 68 Des Voeux Road Central Hong Kong
Hong Kong
HK

NASDAQ OMX Singapore Office

20 Collyer Quay, #17-01
Singapore
SG

NASDAQ OMX Chicago Office

One North Wacker Drive Suite 3600
Chicago
IL
US

NASDAQ OMX Belgium Office

Avenue de Cortenbergh 116
Brussels
BE

NASDAQ OMX Dubai Office

Dubai World Trade Centre Sheikh Zayed Road
Dubai
AE

NASDAQ OMX Tokyo Office

1F, Kojimachi Square Building Nibancho, 3 Chiyoda-ku, Tokyo
Tokyo
JP

NASDAQ OMX Boston Office

100 Franklin St
Boston
MA
US

Location Office

Level 17-19, 110 Bishopsgate
London
GB

Telephone

212 231 5018

Contact

Todd A Swearingen
[email protected]
Back to all NASDAQ OMX announcements

NASDAQ OMX Nordic Welcomes Onxeo SA to its Main Market

NASDAQ OMX Nordic today announced that Onxeo SA is admitted to trading and official listing on NASDAQ OMX Copenhagen. Onxeo is a Mid Cap company in the Health Care sector and will be trading under its short name ONXEO and ISIN code FR0010095596. Onxeo is the 14th company to list at NASDAQ OMX’s Nordic main markets in 2014 (NASDAQ OMX Stockholm; Helsinki; Copenhagen and Iceland).

Onxeo is a company which specialises in the development of medicinal products for the treatment of rare cancer diseases; an area in which Onxeo sees an unmet need for treatment. From August 1 Onxeo is the name of the merged companies BioAlliance Pharma SA and Topotarget A/S. The merger took effect on July 22., 2014. Onxeo has its primary listing on Euronext Paris.

Adam Kostyál, SVP Global Corporate Client Group, NASDAQ OMX Nordic said: “We are very pleased to welcome Onxeo onto the NASDAQ OMX Copenhagen main market, where new investors and existing shareholders can take part in the continued company’s future development. We are proud that Onxeo recognises the value of listing at the NASDAQ OMX Copenhagen exchange and we look forward to partnering with the new company in offering the liquidity and visibility, that a listing on an international exchange can offer.”